INTRODUCTION

Co-infection with HIV and hepatitis B virus (HBV) is common; in the Western world, chronic HBV infection has been found in 6% to 14% among HIV-positive patients. Chronic co-infection with HBV and HIV can lead to increased rates of liver-related morbidity (cirrhosis, hepatocellular carcinoma) and mortality. Prevention of HBV infection is therefore essentially important in the setting of HIV-infection. The success rate of HBV vaccine, however, is much lower in HIV-infected patients as compared with healthy immunocompetent individuals. 90% to 95% of healthy adult individuals develop protective anti-HBV antibody, whereas only 20% to 70% of the HIV-infected patients develop protective anti-HBV antibody after a conventional standard dose of HBV vaccination at 0-1-6 monthly intervals.

Contributing factors associated with nonresponsiveness to HBV vaccination in HIV-infected patients include ongoing HIV-viremia, impaired humoral and cellular immunity, HCV co-infection, and increasing age. The most effective strategy for maximizing HBV-vaccine response in HIV-infected patients remains unknown. Administering doubled HBV vaccine dose, i.e., from 20 to 40 μg, has been tried in several studies with improved overall success rates of 36.6% to 89.5%. In our experience, double-dose HBV rescue vaccination (40 μg HBV vaccination at 0-1-2 monthly intervals) achieved more than 80% seroconversion rates in HIV-infected patients who had failed to respond with conventional standard dose HBV vaccination (20 μg HBV vaccination at 0-1-6 monthly intervals with or without additional 20 μg HBV booster vaccination). Also, it is important to point out that HIV co-infection decreases hepatitis B surface antibody (anti-HBs) persistence in naturally infected...
and conventionally vaccinated individuals. Few data exist to assess the persistence of protective anti-HBs titers after successful double-dose HBV rescue vaccination in the setting of HIV-infection. We reviewed anti-HBs titers a year later in HIV-infected patients who had responded to double-dose HBV rescue vaccination.

**MATERIALS AND METHODS**

A retrospective medical-chart review study was conducted in our center. HIV-infected patients who had failed to develop protective anti-HBs after three or more standard conventional dose HBV vaccine (20 μg HBV vaccination at 0-1-6 monthly intervals with or without additional 20 μg HBV booster vaccination) were identified and were given double-dose HBV rescue vaccination, (40 μg – 20 μg/mL in each deltoid–) (Recombivax HB® (Merck & Co., Inc., Whitehouse Station, NJ, USA) at 0-1-2 monthly intervals. The vaccination schedule was based on a previous study, in which 0-1-2 monthly intervals of standard dose recombinant HBV vaccination resulted in a faster and also identical seroconversion rate to the standard dose recombinant HBV vaccination at 0-1-6 monthly intervals. Patients who developed protective anti-HBs titers of ≥10 mIU/mL after double-dose HBV rescue vaccination were classified as double-dose HBV rescue vaccination responders. These patients had anti-HBs titers assessment 12 months later.

Demographic characteristics, presence of hepatitis C virus (HCV) antibody, CD4 T-cell count, HIV RNA viral load, and use of highly active antiretroviral therapy (HAART) were reviewed at baseline –the time of first double-dose HBV rescue vaccination (at 0 month out of 0-1-2 monthly interval), and at one year follow-up, 12 months after completion of the double-dose HBV rescue vaccination series. Patients who retained anti-HBs titers of ≥10 mIU/mL at one year follow-up were classified as persistent responders (PR) while patients with decreased anti-HBs titers of <10 mIU/mL were defined as nonpersisent responders (NPR).

Statistical analysis was performed using SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, USA). Dichotomous variables were compared using Pearson χ² test or Fisher’s exact test. For continuous variables, Mann-Whitney test was used. Multivariate analysis by logistic regression was used to determine factors associated with successful PR. Odds ratio (OR) and 95% confidence interval (CI) were calculated. A p-value less than 0.05 was considered to be statistically significant.

This study was approved by Institutional Review Board at St. Luke’s-Roosevelt Medical Center, New York, NY, USA.

**RESULTS**

The medical records of HIV-infected patients followed in our center between January 2004 and October 2010 were reviewed. Fifty-four patients received three double-dose HBV rescue vaccine at 0-1-2 monthly intervals after failure to develop protective anti-HBs with three or more conventional standard dose HBV vaccinations. The study population consisted of 41 males (75.9%) with a median age of 45 years. Hispanics and Blacks were the predominant ethnic groups (31/54, 57.4% and 15/54, 27.8%, respectively). Homosexual men (men who have sex with men, MSM) were the major HIV-risk group, 30/54 of patients, 55.6%. Nine patients (9/54, 16.7%) had chronic HCV infection. At the start of the double-dose HBV rescue vaccination series, 49 patients (49/54, 90.7%) were on HAART. The median CD4 T-cell count was 433 cell/mm³ (interquartile range [IQR], 328 to 645 cell/mm³) and 20 patients (20/54, 35.7%) had CD4 T-cell count >500 cell/mm³. The median Log₁₀ HIV viral load was 1.699 (IQR, 1.699 to 2.358) and 30 patients (30/54, 53.6%) had HIV viral load <50 copies/mL. Forty-four patients (44/54, 81.5%)

| Characteristic | Value |
|----------------|-------|
| Total number of patients | 54 |
| Age median [IQR] | 45 (37-50) |
| Sex | |
| Female | 13 (24.1) |
| Male | 41 (75.9) |
| Ethnicity | |
| White | 8 (14.8) |
| Hispanic | 31 (57.4) |
| Black | 15 (27.8) |
| HIV risk factor | |
| Hetero | 18 (33.3) |
| IVDU | 6 (11.1) |
| MSM | 30 (55.6) |
| Hepatitis C co-infection | |
| Hepatitis C positive | 9 (16.7) |
| HAART | |
| On HAART | 49 (90.7) |
| CD4 T-cell count median [IQR] | 433 (328-645) |
| Patients with CD4 >500 | 20 (35.7) |
| Log₁₀ HIV viral load median [IQR] | 1.699 (1.699-2.358) |
| Patients with HIV viral load <50 | 30 (53.6) |
| Double dose HBV rescue vaccine responders | 44 (81.5) |

Values are presented as median (IQR) or number (%).

HBV, hepatitis B virus; IQR, interquartile range; Hetero, heterosexual contact; IVDU, intravenous drug abuse; MSM, men who have sex with men; HAART, highly active antiretroviral therapy; CD4 T-cell cell count cells/mm³, HIV viral load copies/mL; Double-dose HBV rescue vaccine responders, patients who developed protective anti-HBs titers of ≥10 mIU/mL after double-dose HBV rescue vaccination.
developed protective anti-HBs after completion of three double-dose HBV vaccination series (double-dose HBV rescue vaccine responders). The baseline characteristics of patients at the start of double-dose HBV rescue vaccination are shown in Table 1.

Thirty-three of 44 double-dose HBV rescue vaccine responders had follow-up evaluation at one year after the last vaccine dose. Nineteen of the 33 double-dose HBV rescue vaccine responders (19/33, 57.6%) were found to have persistent levels of protective anti-HBs titer ≥10 mIU/mL and they were classified as PR. Fourteen patients (14/33, 42.4%) lost their protective anti-HBs at one year follow-up were defined as NPR. These are shown in Fig. 1. We compared the PR and NPR groups and there was no significant difference in terms of median CD4 T-cell count at baseline or at follow-up. Also the proportions of patients who had CD4 T-cell count >500 cell/mm$^3$ both at baseline and one year follow-up were not different; 4/19, 21.1% in PR group and 3/14, 21.4% in NPR group (p=1.000). Although there was no significant difference in terms of median Log10 HIV viral load at baseline and follow-up between the two groups, the proportion of patients who had undetectable HIV viral load <50 copies/mL both at baseline and follow-up (OR, 12.973; 95% CI, 1.189 to 141.515; p=0.036) was found to be associated with PR among HIV-infected double-dose HBV vaccine recipients as shown in Table 3.

A multivariate logistic regression analysis was performed using the variables of sex, HIV risk factors, presence of HCV antibody, receipt of HAART, CD4 T-cell count, and HIV viral load. Successful HIV viral load suppression defined by undetectable HIV viral load <50 copies/mL both at baseline and follow-up (OR, 12.973; 95% CI, 1.189 to 141.515; p=0.036) was found to be associated with PR among HIV-infected double-dose HBV vaccine recipients as shown in Table 3.

**DISCUSSION**

Our study showed an impressive response rate, 81.5%, of double-dose HBV rescue vaccination series in HIV-infected patients who had prior not responded to conventional HBV vaccination. However, levels of protective anti-HBs titer decreased over a year. 57.6% of double-dose HBV rescue vaccine responders were noted to have persistence of protective anti-HBs titer at one-year follow-up. Our findings are consistent with a previous study in which a high serologic response rate with double-dose HBV vaccination was observed, however, 63% of the responders had persistence of protective anti-HBs titer at 12 months. Also results of our study correspond with the results of earlier study by Cooper et al., in which 89.5% of HIV-infected patients who received double-dose HBV vaccination developed protective anti-HBs titer, and persistence of seroprotective anti-HBs titer was 60% at 24 months of follow-up. Of note, Cooper et al. observed improved durability of the protective anti-HBs titers with the adjuvant CPG 7909 (>80% of patients at 42 to 60 months) compared to those generated by double-dose HBV vaccination without the adjuvant.

We observed that persistence of protective anti-HBs titers in HIV-infected patients at 1 year after double-dose HBV rescue vaccination was associated with HIV viral load suppression.
Table 2. Demographic and Clinical Characteristics at One-Year Follow-Up after Completion of Three Double-Dose Hepatitis B Rescue Vaccinations by Two Groups of Persistent Responders (PR) and Non-Persistent Responders (NPR)

| Characteristic                  | PR (n=19; 19/33, 57.6%) | NPR (n=14; 14/33, 42.4%) | p-value |
|--------------------------------|--------------------------|---------------------------|---------|
| Age median (IQR)               | 42 (39–48)               | 47 (39–52)                | 0.201   |
| Sex                            |                          |                           |         |
| Female                         | 3 (15.8)                 | 4 (28.6)                  | 0.422   |
| Male                           | 16 (84.2)                | 10 (71.4)                 |         |
| Ethnicity                      |                          |                           |         |
| White                          | 5 (26.3)                 | 1 (7.1)                   | 0.209   |
| Hispanic                       | 11 (57.9)                | 6 (42.9)                  | 0.393   |
| Black                          | 3 (15.8)                 | 7 (50.0)                  | 0.057   |
| HIV risk factor                |                          |                           |         |
| Hetero                         | 5 (26.3)                 | 4 (28.6)                  | 1.000   |
| IVDU                           | 0 (0.0)                  | 2 (14.3)                  | 0.172   |
| MSM                            | 14 (73.3)                | 8 (57.1)                  | 0.459   |
| Hepatitis C                    | 1 (5.3)                  | 4 (28.6)                  | 0.138   |
| On HAART                       | 18 (94.7)                | 14 (100.0)                | 1.000   |
| Total number of HBV vaccination median (IQR) | 6.0 (6.0–7.0) | 6.0 (6.0–6.3) | 0.360 |
| CD4 baseline                   | 425 (333–610)            | 386 (290–535)             | 0.308   |
| CD4 follow-up                  | 465 (287–607)            | 465 (273–594)             | 0.855   |
| CD4 >500                       | 4 (21.1)                 | 3 (21.4)                  | 1.000   |
| Log_{10} HIV baseline          | 1.699                    | 1.922                     | 0.103   |
| (1.699–2.057)                  | (1.699–2.867)            |                           |         |
| Log_{10} HIV follow-up         | 1.699                    | 1.766                     | 0.375   |
| (1.699–1.919)                  | (1.699–2.253)            |                           |         |
| HIV viral load <50 copies      | 11 (57.9)                | 3 (21.4)                  | 0.036   |

Values are presented as median (IQR) or number (%).

Table 3. Logistic Regression of Variables Associated with Persistent Responders (PR) at One-Year Follow-Up after Completion of Three Double-Dose Hepatitis B Rescue Vaccinations

| Variable                    | OR (95% CI) | p-value |
|-----------------------------|-------------|---------|
| Sex                         | Female (ref)|         |
| Male                        | 11.329 (0.054–2392.338) | 0.374   |
| HIV risk factor             |             |         |
| Hetero (ref)                |             | 0.999   |
| IVDU (ref)                  | 0.000 (0.000–1) | 0.000   |
| MSM                         | 0.541 (0.004–72.406) | 0.806   |
| Hepatitis C co-infection    |             |         |
| Hepatitis C positive (ref)  |             |         |
| No hepatitis C              | 25.933 (0.977–688.251) | 0.052   |
| HAART                       |             |         |
| No HAART (ref)              |             |         |
| On HAART                    | 0.000 (0.000–1) | 1.000   |
| CD4 T-cell count            |             |         |
| CD4 ≤500 (ref)              |             |         |
| CD4 >500                    | 0.387 (0.047–3.179) | 0.377   |
| HIV viral load              |             |         |
| HIV viral load >50 (ref)    |             |         |
| HIV viral load <50          | 12.973 (1.189–141.515) | 0.036   |

OR, odds ratio; CI, confidence interval; IQR, interquartile range; Hetero, heterosexual contact; IVDU, intravenous drug abuse; MSM, men who have sex with men; HAART, highly active antiretroviral therapy; Hepatitis C, hepatitis C co-infection; total number of HBV vaccinations, includes the conventional standard-dose HBV vaccination and the double-dose HBV rescue vaccination; CD4 baseline and follow-up, CD4 T-cell count cells/mm$^3$ median (IQR) at baseline and follow-up, respectively; CD4 >500, patients who had CD4 T-cell count >500 either at baseline or follow-up; CD4 >500, patients who had CD4 T-cell count >500 both at baseline and follow-up; HIV viral load >50, patients who had detectable HIV viral load >50 either at baseline or follow-up; HIV viral load <50, patients who had undetectable HIV viral load <50 both at baseline and follow-up.

Cell and memory B-cell phenotypes, and reduced memory B-cell proliferative capacity were observed in HIV viremic patients following HBV vaccination. Increased regulatory T cells in HIV-infected patients were found to be associated with nonresponse to HBV vaccine. In addition, an expansion of regulatory T cells has been reported in HIV-infected patients with high HIV viral load. Our results in conjuncture with aforementioned literature further support the notion that maintaining optimal HIV load suppression after double-dose HBV rescue vaccination may play a critical role in persistence of protective anti-HBs titers.

The long-term protective effect of HBV vaccine in HIV-infected patients remains unknown. A recent multicenter observational cohort study of 11,632 person-years of follow-up demonstrated that HIV-infected patients who had achieved a response to HBV vaccine with protective anti-HBs titers ≥10 mIU/mL had a 50% reduced risk of HBV infection compared to those with nonresponse to HBV vaccine. Of the patients with an initial positive HBV vaccine response, risk of HBV infection was

Furthermore our logistic regression analysis supports the role of HIV suppression as an important predictor of persistent anti-HBs titers. Previous studies have also demonstrated that development of anti-HBs responses following HBV vaccination of HIV-infected patients was associated with undetectable HIV viral load. Lower hepatitis B-specific memory B-cell responses, altered B-
not different between those with waning or persistent vaccine responses. It is also interesting that of those vaccine responders who had developed acute HBV infection, none of them developed chronic HBV infection, suggesting benefit from positive response from HBV vaccination for at least 7 years of follow-up. Also long-term memory B cells specific for hepatitis B surface antigen were found in HIV-infected patients with serum anti-HBs titer less than 10 mIU/mL. Therefore, there could be still some benefit for protection against HBV infection even if protective levels of anti-HBs titers may decrease after successful response to double-dose HBV rescue vaccination in HIV-infected patients.

Our study has limitations, however, mostly stemming from its small sample size and its retrospective nature. Eleven of 44 double-dose HBV rescue vaccine responders were not available for one year follow-up evaluation, which might have affected assessment of the durability of persistent protective anti-HBs titers in double-dose HBV rescue vaccine responders. Although factors such as the level of CD4 T-cell count, HAART, and MSM were shown to be associated with HBV vaccine response in HIV-infected patients, our study did not show significant association between these factors and persistence of protective anti-HBs titers. This might reflect one of limitations based on the small sample size due to retrospective nature, not true absence of association. Nonetheless, our cohort of patients might well represent urban HIV-infected patients with access to HIV care in the developed world such as the United States. Therefore, this study results should be of assistance to manage HBV vaccination in urban HIV-infected patients.

In conclusion, double-dose HBV rescue vaccination in HIV-infected patients has demonstrated a higher seroconversion rate of protective anti-HBs titers. Protective levels of anti-HBs titers may decrease over time after successful double-dose HBV rescue vaccination. Optimizing HIV viral load suppression could improve the persistence of protective anti-HBs titers. Achieving protective levels of anti-HBs titers in HIV-infected patients, even if protective levels of anti-HBs titers are decreased, might conceivably provide important protection against chronic HBV infection, and double-dose HBV rescue vaccination should be considered in HIV-infected patients who never responded to conventional or booster HBV vaccination series. Further studies involving a larger number of patients are needed to define the best strategies for improving immune response to HBV vaccination in HIV-infected patients.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

Financial support: none.
Portions of this study were presented at the XVIII International AIDS conference, Vienna Austria, 18-23 July 2010.

REFERENCES

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44:1 Suppl:S56-S59.
2. Kim JH, Psevdos G, Suh J, Sharp VL. Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States. World J Gastroenterol 2008;14:6689-6693.
3. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310.
4. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926.
5. Laurence J. Hepatitis A and B virus immunization in HIV-infected persons. AIDS Read 2006;16:15-17.
6. Overton ET, Singskanupaph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005;41:1045-1048.
7. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008;122:12-19.
8. van der Vliet HJ, von Blomberg BM, Hazenberg MD, et al. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol 2002;168:1490-1495.
9. Quaglio G, Talamini G, Lugoboni F, et al. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction 2002;97:985-992.
10. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002;35:1368-1375.
11. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23:2902-2908.
12. van der Vliet HJ, van Blomberg BM, Hazenberg MD, et al. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV infection. J Immunol 2002;168:1490-1495.
13. de Vries-Sluijs TE, Hansen BE, van Doormum GJ, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197:292-294.
14. Cruciani M, Mengoli C, Serpelloni G, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009;27:17-22.
15. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008;46:1310-1314.

16. Pseudos G, Kim JH, Groce V, Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS 2010;24:403-407.

17. Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994;18:339-347.

18. Mannucci PM, Zanetti AR, Gringeri A, et al. Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med 1989;149:1333-1337.

19. Marsano LS, Greenberg RN, Kirkpatrick RB, et al. Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults. Am J Gastroenterol 1996;91:111-115.

20. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008;19:600-604.

21. Mehta N, Cunningham CK, Flynn P, et al. Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine 2010;28:3672-3678.

22. del Pozo Balado Mdel M, Leal M, Méndez Lagares G, et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010;202:362-369.

23. Rallón NI, López M, Soriano V, et al. Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. Clin Exp Immunol 2009;155:35-43.

24. Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010;24:545-555.

25. Tuillon E, Tabaa YA, Baillat V, Petitjean G, Reynes J, Vendrell JP. Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patients. AIDS 2007;21:2343-2345.

26. Ungulkraiwit P, Jongjirawisan Y, Atamasirikul K, Sungkanuparp S. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. Southeast Asian J Trop Med Public Health 2007;38:680-685.

27. Landrum ML, Huppler Hullsiek K, Ganesan A, et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009;27:4731-4738.

28. Loke RH, Murray-Lyon IM, Coleman JC, Evans BA, Zuckerman AJ. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. J Med Virol 1990;31:109-111.